



浙江大学医学院
ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE

公共技术平台



特邀报告

The Future of Immunohistochemistry

Speaker: Dr. Will Howat

Host: 钟贞 研究员

Date: 4pm, 2019 -10-21

Address: 医学院科研楼辅楼 2楼 玻璃房会议室

The Future of Immunohistochemistry

Validation of antibodies for immunohistochemistry can be a difficult issue and the methods used to determine that an antibody is truly specific needs to be carefully tailored to the target. During this presentation, I will overview my recommended methods for IHC validation which can be used as a base for the next generation immunohistochemical methods. Such methods, such as IHC multiplexing or Nanostring Digital Spatial Multiplexing require a consistent and robust validation to work which will be discussed.



Dr. Will Howat

Dr. Will Howat joined Abcam in August 2018 and is responsible for leading the global Imaging and Immunohistochemistry team. Prior to joining Abcam, he worked at AstraZeneca as the Team Leader of the Molecular Pathology Group, where his team developed biomarker assays for preclinical, Phase 1 and Phase 2 clinical trials. Before that, his academic career spanned the Cancer Research UK Cambridge Institute, Wellcome Sanger Institute, University of Southampton Asthma Research Group and University of Southampton Pathology Department from where he gained his PhD.